All In Biotech

Drug Trial Radar · NCT07549581

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Apr 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Nov 7, 2024

Primary completion

Sep 12, 2025

Study completion Sep 12, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple dose oral administration of SEP-380135 in participants with schizophrenia or with a major depressive episode associated with bipolar I or II disorder or major depressive disorder (MDD).

Conditions

  • Schizophrenia
  • Major Depressive Disorder (MDD)
  • Bipolar Disorder

Interventions

  • SEP-380135Drug

    oral capsule.

  • PlaceboDrug

    Placebo capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) Leading to Trial DiscontinuationTime frame: Up to Day 44
  2. All Cohorts: Percentage of Participants With Suicidal Ideation or Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 18
  3. All Cohorts: Percentage of Participants With Withdrawal Symptoms Using the 20-Item Physician Withdrawal Checklist (PWC-20)Time frame: Up to Day 44
  4. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Laboratory TestsTime frame: Baseline, Day 18
  5. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Vital SignsTime frame: Baseline, Day 18
  6. All Cohorts: Percentage of Participants With Change From Baseline in Potentially Clinically Relevant Orthostatic EffectsTime frame: Baseline, Day 18
  7. All Cohorts: Actual Values of WeightTime frame: Up to Day 18
  8. All Cohorts: Change From Baseline in WeightTime frame: Baseline, Day 18
  9. All Cohorts: Actual Values of Body Mass Index (BMI)Time frame: Up to Day 18
  10. All Cohorts: Change From Baseline in BMITime frame: Baseline, Day 18
  11. All Cohorts: Actual Values of Waist CircumferenceTime frame: Up to Day 18
  12. All Cohorts: Change From Baseline in Waist CircumferenceTime frame: Baseline, Day 18
  13. All Cohorts: Percentage of Participants With Change From Baseline in 12-Lead Electrocardiogram (ECG)Time frame: Baseline, Day 18
  14. All Cohorts: Actual Values of QT interval corrected using Fridericia's Formula (QTcF)Time frame: Up to Day 18
  15. All Cohorts: Change From Baseline in QTcFTime frame: Baseline, Day 18
  16. Cohorts 1, 2, and 3: Actual Values of Clinician-Administered Dissociative States Scale (CADSS) ScoreTime frame: Up to Day 18
  17. Cohorts 1, 2, and 3: Change From Baseline in CADSS ScoreTime frame: Baseline, Day 18
  18. All Cohorts: Actual Values of Drug Effect Questionnaire (DEQ) Scored Using Visual Analog Scale ScoreTime frame: Up to Day 18
  19. All Cohorts: Change From Baseline in DEQ Scored Using Visual Analog Scale ScoreTime frame: Baseline, Day 18
  20. Cohorts 1, 2, and 3: Actual Values of Barnes Akathisia Rating Scale (BARS) ScoreTime frame: Up to Day 18
  21. Cohorts 1, 2, and 3: Change From Baseline in BARS ScoreTime frame: Baseline, Day 18
  22. Cohorts 1, 2, and 3: Actual Values of Abnormal Involuntary Movement Scale (AIMS) ScoreTime frame: Up to Day 18
  23. Cohorts 1, 2, and 3: Change From Baseline in AIMS ScoreTime frame: Baseline, Day 18
  24. Cohorts 1, 2, and 3: Actual Values of Simpson Angus Scale (SAS) ScoreTime frame: Up to Day 18
  25. Cohorts 1, 2, and 3: Change From Baseline in SAS ScoreTime frame: Baseline, Day 18
  26. Cohorts 1, 2, and 3: Actual Values of Positive and Negative Syndrome Scale (PANSS) ScoreTime frame: Up to Day 18
  27. Cohorts 1, 2, and 3: Change From Baseline in PANSS ScoreTime frame: Baseline, Day 18
  28. All Cohorts: Actual Values of Clinical Global Impressions-Severity Scale (CGI-S) ScoreTime frame: Up to Day 18
  29. All Cohorts: Change From Baseline in CGI-S ScoreTime frame: Baseline, Day 18
  30. Cohorts 1, 2, and 3: Actual Values of Calgary Depression Scale for Schizophrenia (CDSS) ScoreTime frame: Up to Day 18
  31. Cohorts 1, 2, and 3: Change From Baseline in CDSS ScoreTime frame: Baseline, Day 18
  32. All Cohorts: Percentage of Participants With Change From Baseline in Physical ExaminationsTime frame: Baseline, Day 18
  33. All Cohorts: Percentage of Participants With Change From Baseline in Neurological ExaminationsTime frame: Baseline, Day 18
  34. Cohort 4: Actual Values of Hamilton Anxiety Rating Scale (HAM-A) ScoreTime frame: Up to Day 18
  35. Cohort 4: Change From Baseline in HAM-A ScoreTime frame: Baseline, Day 18
  36. Cohort 4: Actual Values of Montgomery-Asberg Depression Rating Scale (MADRS) ScoreTime frame: Up to Day 18
  37. Cohort 4: Change From Baseline in MADRS ScoreTime frame: Baseline, Day 18
  38. Cohort 4: Actual Values of Young Mania Rating Scale (YMRS) ScoreTime frame: Up to Day 18
  39. Cohort 4: Change From Baseline in YMRS ScoreTime frame: Baseline, Day 18
  40. All Cohorts: Percentage of Participants With Changes in Quantitative Sleep Parameters Measured Using Electroencephalography (EEG)Time frame: Up to Day 17
  41. All Cohorts: Apparent Clearance (CL/F) of SEP-380135Time frame: Day 14
  42. All Cohorts: Volume of Distribution (Vz/F) of SEP-380135Time frame: Day 14
  43. All Cohorts: Maximum Plasma Concentration (Cmax) of SEP-380135Time frame: Day 14
  44. All Cohorts: Area Under the Drug Concentration-time Curve From Time Zero Predose to 24 hours Postdose (AUC0-24h) of SEP-380135Time frame: Day 14

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.